Peter Hillmen

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 22

Top Venues

British journal of haematology

Clinical cancer research : an official journal of the American Association for Cancer Research

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Blood

This page only lists publications with an associated author ORCID identifier.

Publications

Austin G Kulasekararaj, Jamie Cavenagh, Inderjeet Dokal, Theodora Foukaneli, Shreyans Gandhi, Mamta Garg, Morag Griffin, Peter Hillmen, Robin Ireland, Sally B Killick, Sahar Mansour, Ghulam Mufti, Victoria Potter, John A Snowden, Simon J Stanworth, Roslin Zuha, Judith Marsh, null null
Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline. British journal of haematology (2024)
Austin G Kulasekararaj, Jamie Cavenagh, Inderjeet Dokal, Theodora Foukaneli, Shreyans Gandhi, Mamta Garg, Morag Griffin, Peter Hillmen, Robin Ireland, Sally B Killick, Sahar Mansour, Ghulam Mufti, Victoria Potter, John A Snowden, Simon J Stanworth, Roslin Zuha, Judith Marsh, null null
Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline. British journal of haematology 204 (3) (2024)
Austin G Kulasekararaj, Jamie Cavenagh, Inderjeet Dokal, Theodora Foukaneli, Shreyans Gandhi, Mamta Garg, Morag Griffin, Peter Hillmen, Robin Ireland, Sally B Killick, Sahar Mansour, Ghulam Mufti, Victoria Potter, John A Snowden, Simon J Stanworth, Roslin Zuha, Judith Marsh, null null
Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline. British journal of haematology (2024)
Austin G Kulasekararaj, Jamie Cavenagh, Inderjeet Dokal, Theodora Foukaneli, Shreyans Gandhi, Mamta Garg, Morag Griffin, Peter Hillmen, Robin Ireland, Sally B Killick, Sahar Mansour, Ghulam Mufti, Victoria Potter, John A Snowden, Simon J Stanworth, Roslin Zuha, Judith Marsh, null null
Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline. British journal of haematology 204 (3) (2024)
Louise Carr, Kevin Norris, Helen Parker, Anna Nilsson-Takeuchi, Dean Bryant, Harindra Amarasinghe, Latha Kadalayil, Monica Else, Andrew Pettitt, Peter Hillmen, Anna Schuh, Renata Walewska, Duncan M Baird, David G Oscier, Christopher C Oakes, Jane Gibson, Chris Pepper, Jonathan C Strefford
Telomere length and DNA methylation epitype both provide independent prognostic information in CLL patients; data from the UK CLL4, ARCTIC and ADMIRE clinical trials. British journal of haematology (2024)
Peter Hillmen, Barbara Eichhorst, Jennifer R Brown, Nicole Lamanna, Susan M O'Brien, Constantine S Tam, Lugui Qiu, Maciej Kazmierczak, Keshu Zhou, Martin Simkovic, Jiří Mayer, Amanda Gillespie-Twardy, Mazyar Shadman, Alessandra Ferrajoli, Peter S Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Österborg, Habte A Yimer, Tommi Salmi, Meng Ji, Jessica Yecies, Adam Idoine, Kenneth Wu, Jane Huang, Wojciech Jurczak
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Renata Walewska, Nilima Parry-Jones, Toby Andrew Eyre, George Follows, Nicolas Martinez-Calle, Helen McCarthy, Helen Parry, Piers E M Patten, John Charles Riches, Peter Hillmen, Anna H Schuh
Guideline for the treatment of chronic lymphocytic leukaemia. British journal of haematology 197 (5) (2022)
Tahla Munir, Jake Emmerson, Anna Hockaday, Jamie B Oughton, Dena R Howard, David Phillips, Jeff Neilson, Nicholas Pemberton, Shankara Paneesha, Ben Kennedy, Andy Rawstron, Peter Hillmen
Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial. British journal of haematology 199 (5) (2022)
David John Allsup, Dena R Howard, Jake Emmerson, Anna Hockaday, Andy Rawstron, Jamie B Oughton, Adrian Bloor, David Phillips, Amit Nathwani, Shankara Paneesha, Deborah Turner, Talha Munir, Peter Hillmen
COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study. British journal of haematology 194 (3) (2021)
John C Byrd, Peter Hillmen, Paolo Ghia, Arnon P Kater, Asher Chanan-Khan, Richard R Furman, Susan O'Brien, Mustafa Nuri Yenerel, Arpad Illés, Neil E Kay, Jose A Garcia-Marco, Anthony R Mato, Javier Pinilla-Ibarz, John Francis Seymour, Stephane Lepretre, Stephan Stilgenbauer, Tadeusz Robak, Wayne Rothbaum, Raquel Izumi, Ahmed Hamdy, Priti Patel, Kara Higgins, Sophia Sohoni, Wojciech Jurczak
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (31) (2021)
Toby Andrew Eyre, John Charles Riches, Piers E M Patten, Renata Walewska, Helen Marr, George Follows, Peter Hillmen, Anna H Schuh, null null
Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper. British journal of haematology (2021)
Adam J Linley, Laura I Karydis, Anil Kumar Mondru, Annalisa D'Avola, Humood Al Shmrany, Silvia Cicconi, Rebecca Griffin, Francesco Forconi, Andrew R Pettitt, Nagesh Kalakonda, Andrew C Rawstron, Peter Hillmen, Andrew J Steele, David J MacEwan, Graham Packham, Ian A Prior, Joseph R Slupsky
Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (20) (2021)
Chloe Pek Sang Tang, Gregory Y H Lip, Terry McCormack, Alexander R Lyon, Peter Hillmen, Sunil Iyengar, Nicolas Martinez-Calle, Nilima Parry-Jones, Piers E M Patten, Anna Schuh, Renata Walewska, null null
Management of cardiovascular complications of bruton tyrosine kinase inhibitors. British journal of haematology (2021)
John C Byrd, Jennifer A Woyach, Richard R Furman, Peter Martin, Susan O'Brien, Jennifer R Brown, Deborah M Stephens, Jacqueline C Barrientos, Stephen Devereux, Peter Hillmen, John M Pagel, Ahmed Hamdy, Raquel Izumi, Priti Patel, Min Hui Wang, Nitin Jain, William G Wierda
Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood 137 (24) (2021)
Riccardo Bomben, Francesca Maria Rossi, Filippo Vit, Tamara Bittolo, Tiziana D'Agaro, Antonella Zucchetto, Erika Tissino, Federico Pozzo, Elena Vendramini, Massimo Degan, Eva Zaina, Ilaria Cattarossi, Paola Varaschin, Paola Nanni, Michele Berton, Alessandra Braida, Jerry Polesel, Jared A Cohen, Enrico Santinelli, Annalisa Biagi, Massimo Gentile, Fortunato Morabito, Gilberto Fronza, Gabriele Pozzato, Giovanni D'Arena, Jacopo Olivieri, Pietro Bulian, Christopher J Pepper, Anna Hockaday, Anna Schuh, Peter Hillmen, Davide Rossi, Annalisa Chiarenza, Francesco Zaja, Francesco Di Raimondo, Giovanni Del Poeta, Valter Gattei
TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (20) (2021)
Peter Hillmen, Jing Xie, Alan S M Yong, Catherine Waweru, Thuy Anh Sorof, Ravi K Goyal, Keith L Davis
Real-world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK. EJHaem 2 (2) (2021)
Arnon P Kater, Jenny Qun Wu, Thomas J Kipps, Barbara Eichhorst, Peter Hillmen, James D'Rozario, Sarit E Assouline, Carolyn Owen, Tadeusz Robak, Javier de laSerna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Julie Dubois, Eric Eldering, Clemens Mellink, Anne-Marie F van der Kevie-Kersemaekers, Su Young Kim, Brenda Chyla, Elizabeth Punnoose, Christopher R Bolen, Zoe June Assaf, Yanwen Jiang, Jue Wang, Marcus Lefebure, Michelle Boyer, Kathryn Humphrey, John Francis Seymour
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 38 (34) (2020)
Matthew S Davids, Bryone J Kuss, Peter Hillmen, Marco Montillo, Carol Moreno, James Essell, Nicole Lamanna, Zsolt Nagy, Constantine S Tam, Stephan Stilgenbauer, Paolo Ghia, Julio Delgado, Stephanie Lustgarten, David T Weaver, Hagop Youssoufian, Ulrich Jäger
Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (9) (2020)
Alexey V Danilov, Charles Herbaux, Harriet Sarah Walter, Peter Hillmen, Simon A Rule, Ebenezer A Kio, Lionel Karlin, Martin J S Dyer, Siddhartha S Mitra, Ping Cheng Yi, Rita Humeniuk, Xi Huang, Ziqian Zhou, Pankaj Bhargava, Juliane M Jürgensmeier, Christopher D Fegan
Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (12) (2020)
Farrukh T Awan, Anna Schuh, Jennifer R Brown, Richard R Furman, John M Pagel, Peter Hillmen, Deborah M Stephens, Jennifer Woyach, Elena Bibikova, Prista Charuworn, Melanie M Frigault, Ahmed Hamdy, Raquel Izumi, Bolan Linghu, Priti Patel, Min Hui Wang, John C Byrd
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood advances 3 (9) (2020)
Ian W Flinn, John G Gribben, Martin J S Dyer, William Wierda, Michael B Maris, Richard R Furman, Peter Hillmen, Kerry A Rogers, Swaminathan Padmanabhan Iyer, Anne Quillet-Mary, Loic Ysebaert, Harriet S Walter, Maria Verdugo, Christian Klein, Huang Huang, Yanwen Jiang, Gerard Lozanski, Daniela Soriano Pignataro, Kathryn Humphrey, Mehrdad Mobasher, Thomas J Kipps
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood 133 (26) (2019)
John C Byrd, Peter Hillmen, Susan O'Brien, Jacqueline C Barrientos, Nishitha M Reddy, Steven Coutre, Constantine S Tam, Stephen P Mulligan, Ulrich Jaeger, Paul M Barr, Richard R Furman, Thomas J Kipps, Patrick Thornton, Carol Moreno, Marco Montillo, John M Pagel, Jan A Burger, Jennifer A Woyach, Sandra Dai, Remus Vezan, Danelle F James, Jennifer R Brown
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood 133 (19) (2019)

Peter Hillmen.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Peter Hillmen